NCT07118878View on ClinicalTrials.gov

A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2025

Conditions

Fibrostenotic Crohn's Disease

Interventions

DRUG

AGMB-129

AGMB-129

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

RECRUITING

SGS Belgium, Edegem

All Listed Sponsors

lead

Agomab Spain S.L.

INDUSTRY